Myriad Genetics Q1 EPS Estimate Reduced by Leerink Partnrs

Myriad Genetics, Inc. (NASDAQ:MYGN) – Equities research analysts at Leerink Partnrs lowered their Q1 2025 EPS estimates for Myriad Genetics in a report released on Tuesday, February 25th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.18) per share for the quarter, down from their prior forecast of ($0.08). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Myriad Genetics’ current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics’ Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.16) EPS.

MYGN has been the topic of a number of other reports. The Goldman Sachs Group dropped their target price on shares of Myriad Genetics from $29.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Stephens reissued an “equal weight” rating and issued a $20.00 price objective on shares of Myriad Genetics in a research note on Thursday, January 16th. UBS Group decreased their target price on Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a research report on Tuesday. StockNews.com lowered Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Finally, Morgan Stanley lowered their price objective on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a research note on Monday, November 18th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $22.14.

Myriad Genetics Trading Down 4.2 %

NASDAQ MYGN opened at $11.07 on Friday. The stock has a market cap of $1.01 billion, a PE ratio of -8.52 and a beta of 1.88. Myriad Genetics has a 12 month low of $9.76 and a 12 month high of $29.30. The company’s 50-day moving average price is $13.33 and its 200-day moving average price is $19.16. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The business had revenue of $210.60 million during the quarter, compared to analysts’ expectations of $210.35 million. During the same quarter in the previous year, the company posted ($0.12) earnings per share.

Hedge Funds Weigh In On Myriad Genetics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Myriad Genetics by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 10,591,043 shares of the company’s stock valued at $145,203,000 after purchasing an additional 279,379 shares in the last quarter. State Street Corp increased its position in shares of Myriad Genetics by 8.3% in the third quarter. State Street Corp now owns 4,703,442 shares of the company’s stock valued at $128,827,000 after buying an additional 359,685 shares in the last quarter. Earnest Partners LLC lifted its position in shares of Myriad Genetics by 0.4% during the 4th quarter. Earnest Partners LLC now owns 3,971,598 shares of the company’s stock valued at $54,451,000 after buying an additional 15,650 shares in the last quarter. Artisan Partners Limited Partnership grew its stake in Myriad Genetics by 13.9% in the 4th quarter. Artisan Partners Limited Partnership now owns 2,766,729 shares of the company’s stock valued at $37,932,000 after acquiring an additional 336,770 shares during the period. Finally, Disciplined Growth Investors Inc. MN raised its position in Myriad Genetics by 21.1% during the third quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock worth $69,226,000 after acquiring an additional 440,107 shares during the period. Institutional investors and hedge funds own 99.02% of the company’s stock.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.